Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Atrial Flutter Treatment & Management

  • Author: M Silvana Horenstein, MD; Chief Editor: Steven R Neish, MD, SM  more...
 
Updated: Feb 11, 2014
 

Approach Considerations

In children with atrial flutter, medical care should be broadly directed at the following:

  • Ensuring hemodynamic stability before, during, and after conversion to sinus rhythm
  • Minimizing influences favoring initiation or maintenance of atrial arrhythmias (eg, electrolyte disturbances, pericardial effusion, indwelling atrial lines or catheters)
  • Excluding or managing complications (eg, ventricular dysfunction, thromboembolic phenomena)
  • Restoring

Drug therapy may be indicated in some children with atrial flutter. Drug therapy in these cases can be classified under the 3 broad headings of ventricular rate control, acute conversion, and chronic suppression.

Thrombosis and thromboembolic events are recognized complications in patients with atrial flutter, particularly in the setting of repaired congenital heart disease. Patients who have thrombi identified on transesophageal echocardiography or have a history of chronic atrial flutter (>2 wk duration) should be treated with a period of anticoagulation (2-4 wk), if hemodynamically and symptomatically tolerated, before undergoing direct current (DC) cardioversion or other conversion of their rhythm.

According to a legal precedent, patients with Mustard repair of transposition of the great vessels and sick sinus syndrome should not receive quinidine without a previously implanted pacemaker. However, quinidine is now recognized to have a detrimental adverse effect profile in general, and it is essentially no longer used in the treatment of rhythm disorders following congenital heart disease. Disagreement surrounds whether this recommendation should be extrapolated to other antiarrhythmics and other forms of repaired congenital heart disease.

Go to Atrial Flutter and Emergent Management of Atrial Flutter for complete information on these topics.

Transfer considerations

As with most symptomatic arrhythmias, conversion should ideally be achieved before transfer, except in the case of a hemodynamically stable patient referred to an institution with clearly superior expertise and facilities for management of pediatric atrial flutter.

Next

Programmable Stimulation

Pace-termination of atrial flutter is best performed with a programmable stimulator that is capable of sensing atrial electrograms and delivering single, double, or multiple extrastimuli at adequate output and individually programmable cycle lengths down to 100 milliseconds.

Short discrete ramps or bursts of atrial stimuli are the most likely to produce a type I conversion of atrial flutter (immediate conversion to sinus rhythm), particularly if they can be delivered in or near the flutter circuit. If such a device is unavailable, a pacemaker capable of burst pacing at a specified rate may be used.

If pacing is performed via an esophageal electrode, the device should be capable of delivering stimuli at pulse widths of 9.9-20 milliseconds and outputs of 10-26 mA.

Patients who are treated with atrial antitachycardia pacing should undergo testing to confirm that their device is effective and not proarrhythmic.

Previous
Next

Cardioversion

R-wave synchronized cardioversion is the mainstay of therapy in patients who are unstable or if other therapies have failed. In patients who are stable and have chronic atrial flutter, perform cardioversion only after documentation of freedom from intracardiac thrombi or following a 2-week course of anticoagulation.

Cardioversion may be performed at increasing doses of 0.5, 1, 2, and 4 J/kg. Newer biphasic waveform defibrillators may allow for lower energy applications.[14]

Ideally, place defibrillator paddles or pads in an anteroposterior configuration, with the apex paddle located over the mid sternum and the base paddle between the scapulae. An anesthesiologist usually administers a brief general anesthetic, except in truly emergent circumstances that mandate immediate cardioversion.

Hemodynamic instability requires immediate cardioversion as described above. However, patients who are relatively stable may be allowed to remain in flutter while careful consideration of possible interventions is undertaken. The patient should rest in a supine position without undue excitement or agitation. Consider digoxin if not already in use because it frequently increases the conduction ratio and decreases the ventricular rate. However, this effect usually takes many hours.

Medications with the potential to slow the atrial rate without affecting the atrioventricular (AV) node should be used with caution because the conduction ratio often decreases to 1:1 AV association. This may result in a rapid ventricular rate and hemodynamic compromise.

Avoid adrenergic and atropinic agents during sedation or anesthesia for cardioversion. Ketamine is relatively contraindicated. Such agents may result in rapid 1:1 AV conduction, with resultant hemodynamic compromise. On the other hand, insufficient sedation during attempted esophageal overdrive pacing or a failed cardioversion may result in patient distress and 1:1 AV conduction ratio.

Previous
Next

Radiofrequency Catheter Ablation

Currently, radiofrequency catheter ablation appears to be somewhat effective in treating postoperative intra-atrial reentrant tachycardia in children.

Because the flutter circuits and critical isthmuses are quite variable in these patients, mapping of flutter circuits may be enhanced by 3-dimensional electroanatomical display systems, identification of split potentials, and demonstration of concealed entrainment during pacing.

Previous
Next

Surgical Correction of Atrial Flutter

In patients with atrial flutter, surgical care may include one of the following procedures:

  • Correction of hemodynamic lesions that could be causing atrial volume loading
  • Specifically placed atrial incisions or cryoablation prophylactically to prevent atrial flutter
  • Empiric or map-directed lesions to eliminate documented atrial flutter and its circuits

These surgeries include various modifications and updates to maze procedures and modifications of the Mustard and Fontan procedures. One study reported that a right-sided maze procedure in patients with atrial flutter or fibrillation undergoing congenital heart disease repair significantly reduced arrhythmia recurrence at a mean of 2.7 y after surgery.[15] )

Previous
Next

Activity Restriction

Aggressive strategies to convert atrial flutter and maintain sinus rhythm should be pursued in children. In rare cases of resistant chronic atrial flutter when only rate control can be accomplished, patients should avoid competitive sports. Also restrict the activities of patients likely to develop rapid conduction of intermittent acute episodes of flutter.

Previous
Next

Deterrence/Prevention of Atrial Flutter

Atrial stretch, surgical scarring, and sinus node dysfunction all appear to play important roles in the development of atrial flutter in patients with congenital heart disease. The development of new surgical techniques to avoid atrial suture lines or dilatation and to prophylactically interrupt potential conduction isthmuses within the atria may reduce the frequency of this disorder in future surgical cohorts of patients with congenital heart disease.

Efforts directed at sparing the sinus node during surgery, coupled with more aggressive pacing strategies in patients with sinus node dysfunction, could also play an important role in prevention of atrial flutter.

Previous
 
 
Contributor Information and Disclosures
Author

M Silvana Horenstein, MD Assistant Professor, Department of Pediatrics, University of Texas Medical School at Houston; Medical Doctor Consultant, Legacy Department, Best Doctors, Inc

M Silvana Horenstein, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Robert Murray Hamilton, MD, MSc, FRCPC Electrophysiologist, Senior Associate Scientist, Physiology and Experimental Medicine, Labatt Family Heart Centre; Professor, Department of Pediatrics, University of Toronto Faculty of Medicine

Robert Murray Hamilton, MD, MSc, FRCPC is a member of the following medical societies: American Heart Association, Canadian Medical Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Canadian Medical Protective Association, Heart Rhythm Society, Canadian Cardiovascular Society, Cardiac Electrophysiology Society, Pediatric and Congenital Electrophysiology Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Steven R Neish, MD, SM Director of Pediatric Cardiology Fellowship Program, Associate Professor, Department of Pediatrics, Baylor College of Medicine

Steven R Neish, MD, SM is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association

Disclosure: Nothing to disclose.

Acknowledgements

Alvin J Chin, MD Professor of Pediatrics, University of Pennsylvania School of Medicine; Attending Physician, Cardiology Division, Children's Hospital of Philadelphia

Alvin J Chin, MD, is a member of the following medical societies: American Association for the Advancement of Science, American Heart Association, and Society for Developmental Biology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Biviano A, Garan H, Hickey K, Whang W, Dizon J, Rosenbaum M. Atrial flutter catheter ablation in adult patients with repaired tetralogy of Fallot: mechanisms and outcomes of percutaneous catheter ablation in a consecutive series. J Interv Card Electrophysiol. 2010 Aug. 28(2):125-35. [Medline].

  2. Boriani G, Gallina M, Merlini L, et al. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke. 2003 Apr. 34(4):901-8. [Medline].

  3. Nazarian S, Wagner KR, Caffo BS, Tomaselli GF. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol. 2011 Feb. 34(2):171-6. [Medline]. [Full Text].

  4. Frost L, Hune LJ, Vestergaard P. Overweight, obesity and risk factors for atrial fibrillation or flutter--secondary publication.The cohort study Diet, Cancer and Health. Ugeskr Laeger. 2005 Sep 12. 167(37):3507-9. [Medline].

  5. Frost L, Vestergaard P. Alcohol consumption and the risk of atrial fibrillation or flutter--secondary publication. A cohort study. Ugeskr Laeger. 2005 Aug 29. 167(35):3308-10. [Medline].

  6. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter--secondary publication. A population-based study. Ugeskr Laeger. 2005 Aug 29. 167(35):3305-7. [Medline].

  7. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005 Dec 7. 105(3):315-8. [Medline].

  8. Earing MG, Cetta F, Driscoll DJ. Long-term results of the Fontan operation for double-inlet left ventricle. Am J Cardiol. 2005 Jul 15. 96(2):291-8. [Medline].

  9. Balaji S, Daga A, Bradley DJ, Etheridge SP, Law IH, Batra AS, et al. An international multicenter study comparing arrhythmia prevalence between the intracardiac lateral tunnel and the extracardiac conduit type of Fontan operations. J Thorac Cardiovasc Surg. 2013 Oct 27. [Medline].

  10. Krapp M, Kohl T, Simpson JM. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003 Aug. 89(8):913-7. [Medline].

  11. Southall DP, Johnson AM, Shinebourne EA, Johnston PG, Vulliamy DG. Frequency and outcome of disorders of cardiac rhythm and conduction in a population of newborn infants. Pediatrics. 1981 Jul. 68(1):58-66. [Medline].

  12. Silversides CK, Harris L, Haberer K. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006 Apr 15. 97(8):1206-12. [Medline].

  13. Liberman L, Pass RH, Starc TJ. Optimal surface electrocardiogram lead for identification of the mechanism of supraventricular tachycardia in children. Pediatr Emerg Care. 2008 Jan. 24(1):28-30. [Medline].

  14. Liberman L, Hordof AJ, Altmann K, Pass RH. Low energy biphasic waveform cardioversion of atrial arrhythmias in pediatric patients and young adults. Pacing Clin Electrophysiol. 2006 Dec. 29(12):1383-6. [Medline].

  15. Stulak JM, Dearani JA, Puga FJ. Right-sided Maze procedure for atrial tachyarrhythmias in congenital heart disease. Ann Thorac Surg. 2006 May. 81(5):1780-4; discussion 1784-5. [Medline].

  16. Naccarelli GV, Wolbrette DL, Levin V, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011. 5:103-19. [Medline]. [Full Text].

  17. Oudijk MA, Ruskamp JM, Ververs FF, et al. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol. 2003 Aug 20. 42(4):765-70. [Medline].

  18. Rebelo M, Macedo AJ, Nogueira G, Trigo C, Kaku S. Sotalol in the treatment of fetal tachyarrhythmia. Rev Port Cardiol. 2006 May. 25(5):477-81. [Medline].

 
Previous
Next
 
Rhythm strip depicting lead II of a patient with atrial flutter with an atrial rate of 300 beats per minute (bpm). Atrioventricular conduction rate is variable at 2:1 and 3:1. Therefore, the ventricular rate ranges from 100-150 bpm.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.